Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224661 · ClinicalTrials.gov registry record
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
A clinical trial of Acute Myeloid Leukemia in Remission, sponsored by Center for International Blood and Marrow Transplant Research.
- Active
- Registry status
- 303
- Enrollment target
- 18
- Study locations
NCT05224661 is a study of Acute Myeloid Leukemia in Remission that is active but no longer recruiting, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 303 participants, above the 42-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (621% higher). The trial reports 18 study locations across 11 states.
The verdict
NCT05224661, a study of Acute Myeloid Leukemia in Remission, is active but no longer recruiting, sponsored by Center for International Blood and Marrow Transplant Research.
- ACTIVE NOT RECRUITING
- Registry status
- 303 participants
- Enrollment target
- 18
- Study locations
Study Summary
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Conditions Studied
Interventions
- OTHER Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Study Locations (18)
California
- City of Hope - Duarte
- University of California, San Francisco - San Francisco
- Stanford University - Stanford
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
- New York Presbyterian / Weill Cornell Medical Center - New York
Florida
- University of Miami - Miami
- H. Lee Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Colorado
- University of Colorado - Aurora
Georgia
- Northside Hospital - Atlanta
Illinois
- University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2029-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224661
The ClinicalTrials.gov registry entry for NCT05224661 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (621% higher). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia in Remission appearing as the primary indexed condition, and to 1 intervention - of which Prospective determination of the clinical utility of measurable residual disease (MRD) testing is the first listed.
NCT05224661 reports 18 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05224661 about?
NCT05224661 is a clinical study titled "Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events". Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
What is the current status of trial NCT05224661?
This trial is currently active not recruiting. The enrollment target is 303 participants. The study started on 2022-08-26. Estimated completion is 2029-07-01.
What conditions does trial NCT05224661 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia in Remission.
What interventions are being tested in trial NCT05224661?
The interventions under investigation include: Prospective determination of the clinical utility of measurable residual disease (MRD) testing (OTHER).
Who is sponsoring clinical trial NCT05224661?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05224661 being conducted?
This trial has 18 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia in Remission
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RECRUITING · Phase 1
-
Ziftomenib Maintenance Post Allo-HCT
RECRUITING · Phase 1
-
Pilot Study of Reduced Venetoclax Exposure
RECRUITING · Phase 2
-
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
RECRUITING · NA
-
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.